| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
ROVI Stock Overview
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally.
Laboratorios Farmaceuticos Rovi, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €36.20 |
| 52 Week High | €74.90 |
| 52 Week Low | €35.68 |
| Beta | 0.45 |
| 1 Month Change | -5.24% |
| 3 Month Change | -22.48% |
| 1 Year Change | -45.56% |
| 3 Year Change | 45.97% |
| 5 Year Change | 117.42% |
| Change since IPO | 262.00% |
Recent News & Updates
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Nov 04
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
Sep 15Recent updates
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely
Nov 04Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?
Sep 15Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?
Aug 28Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly
Jun 15I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease
Feb 13Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?
Jan 02A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Dec 12Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Nov 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Sep 24Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching
Jun 02We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt
Apr 06Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%
Mar 15If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late
Feb 16
Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?
Jan 26These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well
Jan 04Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years
Dec 14Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?
Nov 26Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jul 06Shareholder Returns
| ROVI | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | -2.3% | -0.4% | -2.2% |
| 1Y | -45.6% | 0.5% | -3.6% |
Return vs Industry: ROVI underperformed the Spanish Pharmaceuticals industry which returned 0.9% over the past year.
Return vs Market: ROVI underperformed the Spanish Market which returned -3.5% over the past year.
Price Volatility
| ROVI volatility | |
|---|---|
| ROVI Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in ES Market | 6.5% |
| 10% least volatile stocks in ES Market | 0.6% |
Stable Share Price: ROVI is more volatile than 75% of Spanish stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ROVI's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 1,852 | Juan Lopez-Belmonte Encina | https://www.rovi.es |
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers.
Laboratorios Farmaceuticos Rovi, S.A. Fundamentals Summary
| ROVI fundamental statistics | |
|---|---|
| Market Cap | €1.93b |
| Earnings (TTM) | €175.64m |
| Revenue (TTM) | €760.67m |
11.0x
P/E Ratio2.5x
P/S RatioIs ROVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROVI income statement (TTM) | |
|---|---|
| Revenue | €760.67m |
| Cost of Revenue | €303.51m |
| Gross Profit | €457.17m |
| Other Expenses | €281.52m |
| Earnings | €175.64m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.29 |
| Gross Margin | 60.10% |
| Net Profit Margin | 23.09% |
| Debt/Equity Ratio | 12.4% |
How did ROVI perform over the long term?
See historical performance and comparison